4//SEC Filing
Thakkar Roopal 4
Accession 0001415889-24-004421
CIK 0001551152other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:15 PM ET
Size
14.1 KB
Accession
0001415889-24-004421
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Thakkar Roopal
EVP, R&D and CSO
Transactions
- Award
Common Stock, $0.01 par value
2024-02-15+8,022→ 18,399 total - Award
Common Stock, $0.01 par value
2024-02-15+2,138→ 20,537 total - Award
Common Stock, $0.01 par value
2024-02-15+1,844→ 22,381 total - Award
Common Stock, $0.01 par value
2024-02-15+5,792→ 28,173 total - Award
Option (Right to buy)
2024-02-15+13,868→ 13,868 totalExercise: $0.00From: 2025-02-15Exp: 2034-02-14→ Common Stock (13,868 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0002004979
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 5:15 PM ET
- Size
- 14.1 KB